149 related articles for article (PubMed ID: 18391597)
21. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Dragovich T; Burris H; Loehrer P; Von Hoff DD; Chow S; Stratton S; Green S; Obregon Y; Alvarez I; Gordon M
Am J Clin Oncol; 2008 Apr; 31(2):157-62. PubMed ID: 18391600
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Kessler ER; Eckhardt SG; Pitts TM; Bradshaw-Pierce EL; O'byrant CL; Messersmith WA; Nallapreddy S; Weekes C; Spratlin J; Lieu CH; Kane MA; Eppers S; Freas E; Leong S
Invest New Drugs; 2016 Apr; 34(2):176-83. PubMed ID: 26715573
[TBL] [Abstract][Full Text] [Related]
24. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Lassen U; Jensen LH; Sorensen M; Rohrberg KS; Ujmajuridze Z; Jakobsen A
Acta Oncol; 2011 Apr; 50(3):448-54. PubMed ID: 20670085
[TBL] [Abstract][Full Text] [Related]
25. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
Starling N; Hawkes EA; Chau I; Watkins D; Thomas J; Webb J; Brown G; Thomas K; Barbachano Y; Oates J; Cunningham D
Ann Oncol; 2012 Apr; 23(4):942-7. PubMed ID: 21750117
[TBL] [Abstract][Full Text] [Related]
26. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
[TBL] [Abstract][Full Text] [Related]
27. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.
van der Noll R; Smit WM; Wymenga AN; Boss DS; Grob M; Huitema AD; Rosing H; Tibben MM; Keessen M; Rehorst H; Beijnen JH; Schellens JH
Invest New Drugs; 2015 Dec; 33(6):1197-205. PubMed ID: 26362459
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
Verderame F; Russo A; Di Leo R; Badalamenti G; Santangelo D; Cicero G; Valerio MR; Gulotta G; Tomasello G; Gebbia N; Fulfaro F
Ann Oncol; 2006 Jun; 17 Suppl 7():vii68-72. PubMed ID: 16760298
[TBL] [Abstract][Full Text] [Related]
30. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
Okano N; Morizane C; Nomura S; Takahashi H; Tsumura H; Satake H; Mizuno N; Tsuji K; Shioji K; Asagi A; Yasui K; Kitagawa S; Kashiwada T; Ishiguro A; Kanai M; Ueno M; Ogura T; Shimizu S; Tobimatsu K; Motoya M; Nakashima K; Ikeda M; Okusaka T; Furuse J
Int J Clin Oncol; 2020 Oct; 25(10):1835-1843. PubMed ID: 32535711
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer.
Isayama H; Nakai Y; Yamamoto K; Sasaki T; Mizuno S; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Arizumi T; Togawa O; Ito Y; Matsubara S; Yamamoto N; Sasahira N; Hirano K; Tsujino T; Tada M; Omata M; Koike K
Oncology; 2011; 80(1-2):97-101. PubMed ID: 21677453
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.
Kullmann F; Hollerbach S; Dollinger MM; Harder J; Fuchs M; Messmann H; Trojan J; Gäbele E; Hinke A; Hollerbach C; Endlicher E
Br J Cancer; 2009 Apr; 100(7):1032-6. PubMed ID: 19293797
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.
Alberts SR; Townley PM; Goldberg RM; Cha SS; Sargent DJ; Moore DF; Krook JE; Pitot HC; Fitch TR; Wiesenfeld M; Mailliard JA
Ann Oncol; 2003 Apr; 14(4):580-5. PubMed ID: 12649105
[TBL] [Abstract][Full Text] [Related]
37. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
[TBL] [Abstract][Full Text] [Related]
38. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Iannitti D; Dipetrillo T; Akerman P; Barnett JM; Maia-Acuna C; Cruff D; Miner T; Martel D; Cioffi W; Remis M; Kennedy T; Safran H
Am J Clin Oncol; 2005 Dec; 28(6):570-5. PubMed ID: 16317266
[TBL] [Abstract][Full Text] [Related]
39. [Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
Jiang Y; Zhong H; He P; Zheng L; Yang K
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):472-5. PubMed ID: 26463154
[TBL] [Abstract][Full Text] [Related]
40. Her signaling in pancreatic cancer.
Burtness B
Expert Opin Biol Ther; 2007 Jun; 7(6):823-9. PubMed ID: 17555368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]